The mechanism is thought to involve FAK (focal adhesion kinase) and paxillin signaling, but the specific binding target for BPC 157 on a cell surface receptor has not been definitively identified and published as of 2026
99.4% average purity across published reports), searchable by batch code at certapeptides.com/verify
Instead, it furnishes antioxidant protection, supports texture in the skin, and hydrates the skin
However, the 15-amino-acid size and susceptibility to peptidase degradation at mucosal surfaces are meaningful barriers that have not been formally quantified for BPC 157 specifically
Specifically, a review of clinical trials on the use of BPC-157 has characterized it as safe both in treating inflammatory bowel disease and wound healing, noting that no events of toxicity had been reported throughout those trials.